320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer

• Pawel Kalinski,
• Peter Forsyth,
• Mateusz Opyrchal,
• Hung Khong,
• Amy Early,
• Brian Czerniecki,
• Shipra Gandhi,
• Kamran Ahmed,
• Kristopher Attwood,
• Ellis Levine,
• Tracey O’Connor,
• Robert Fenstermaker,
• Dheerendra Prasad,
• Kazuaki Takabe

Affiliations

Pawel Kalinski

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Peter Forsyth

2Moffitt Cancer Center, Tampa, FL, USA

Mateusz Opyrchal

3Washington University, St. Louis, MO, USA

Hung Khong

2Moffitt Cancer Center, Tampa, FL, USA

Amy Early

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Brian Czerniecki

2Moffitt Cancer Center, Tampa, FL, USA

Shipra Gandhi

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Kamran Ahmed

2Moffitt Cancer Center, Tampa, FL, USA

Kristopher Attwood

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Ellis Levine

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Tracey O’Connor

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Robert Fenstermaker

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Dheerendra Prasad

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Kazuaki Takabe

1Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA